This article has been updated from a previous version to include comments from Seryx.
Researchers from Johns Hopkins University's Genetics and Public Policy Center last week said they uncovered inconsistencies and misleading claims made by companies selling CYP450 testing services designed to help guide treatments of certain antidepressants.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.